Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Voyager Therapeutics to Present at Investor Conferences in October

Posted on: 03 Oct 17

CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences:

  • Chardan Gene Therapy Conference, New York City
    Date: Tuesday, October 10, 2017
    Time: 9:00 a.m. EDT
    Panel Members:  Jane Henderson, chief financial officer and senior vice president of corporate development and Bernard Ravina, M.D., M.S., chief medical officer 
  • Jefferies Gene Technology Investor Summit, New York City
    Date: Thursday, October 12, 2017
    Time: 3:30 p.m. EDT
    Panel Members: Jane Henderson, chief financial officer and senior vice president of corporate development and Dinah Sah, Ph.D., chief scientific officer  

Live-streaming webcasts of these presentations can be accessed through the Investors & Media section of Voyager’s website at  The webcast will be archived for 30 days after the live event concludes.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of adeno-associated virus (AAV) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. Voyager’s pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.  Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School.  Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts.  For more information, please visit

CONTACT: Investor Relations:    Matt Osborne Head of Investor Relations & Corporate Communications 857-259-5353   Media:            Katie Engleman Pure Communications, Inc. 910-509-3977 Katie@purecommunicationsinc.comGlobeNewswire

Last updated on: 04/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.